TrialRheumatology (Oxford, England)2022

Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis.

Christopher P Denton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.